Sigma Of Australia Faces Aspen Takeover At Fire-Sale Price
This article was originally published in PharmAsia News
Executive Summary
Australia's Sigma Pharmaceuticals and its shareholders face a dilemma set up by Aspen Pharmacare of South Africa of accepting capital losses and selling their shares for what they can, given the financial and leadership disarray within the Aussie firm